| Tbio | Transcriptional adapter 2-alpha |
Component of the ATAC complex, a complex with histone acetyltransferase activity on histones H3 and H4. Required for the function of some acidic activation domains, which activate transcription from a distant site (By similarity). Binds double-stranded DNA. Binds dinucleosomes, probably at the linker region between neighboring nucleosomes. Plays a role in chromatin remodeling. May promote TP53/p53 'Lys-321' acetylation, leading to reduced TP53 stability and transcriptional activity (PubMed:22644376). May also promote XRCC6 acetylation thus facilitating cell apoptosis in response to DNA damage (PubMed:22644376).
Many DNA-binding transcriptional activator proteins enhance the initiation rate of RNA polymerase II-mediated gene transcription by interacting functionally with the general transcription machinery bound at the basal promoter. Adaptor proteins are usually required for this activation, possibly to acetylate and destabilize nucleosomes, thereby relieving chromatin constraints at the promoter. The protein encoded by this gene is a transcriptional activator adaptor and has been found to be part of the PCAF histone acetylase complex. Several alternatively spliced transcript variants encoding different isoforms of this gene have been described, but the full-length nature of some of these variants has not been determined. [provided by RefSeq, Oct 2009]
Many DNA-binding transcriptional activator proteins enhance the initiation rate of RNA polymerase II-mediated gene transcription by interacting functionally with the general transcription machinery bound at the basal promoter. Adaptor proteins are usually required for this activation, possibly to acetylate and destabilize nucleosomes, thereby relieving chromatin constraints at the promoter. The protein encoded by this gene is a transcriptional activator adaptor and has been found to be part of the PCAF histone acetylase complex. Several alternatively spliced transcript variants encoding different isoforms of this gene have been described, but the full-length nature of some of these variants has not been determined. [provided by RefSeq, Oct 2009]
Comments
| Disease | Target Count | P-value |
|---|---|---|
| glioblastoma | 5792 | 3.9e-07 |
| malignant mesothelioma | 3232 | 3.8e-06 |
| atypical teratoid / rhabdoid tumor | 5112 | 1.9e-05 |
| pediatric high grade glioma | 1064 | 1.0e-04 |
| osteosarcoma | 7950 | 1.7e-04 |
| lung cancer | 4740 | 6.2e-04 |
| psoriasis | 6694 | 3.7e-03 |
| Disease | Target Count | Z-score | Confidence |
|---|---|---|---|
| Chromosome 17q12 deletion syndrome | 16 | 5.322 | 2.7 |
| VACTERL association | 26 | 4.191 | 2.1 |
| Imperforate anus | 25 | 3.641 | 1.8 |
| Edwards syndrome | 17 | 3.363 | 1.7 |
| Esophageal atresia | 43 | 3.224 | 1.6 |
| Congenital diaphragmatic hernia | 67 | 3.017 | 1.5 |
| Disease | log2 FC | p |
|---|---|---|
| atypical teratoid / rhabdoid tumor | -1.300 | 1.9e-05 |
| glioblastoma | -1.500 | 3.9e-07 |
| lung cancer | 1.200 | 6.2e-04 |
| malignant mesothelioma | 1.400 | 3.8e-06 |
| osteosarcoma | -1.180 | 1.7e-04 |
| pediatric high grade glioma | -1.100 | 1.0e-04 |
| psoriasis | -1.100 | 3.7e-03 |
MDRLGPFSNDPSDKPPCRGCSSYLMEPYIKCAECGPPPFFLCLQCFTRGFEYKKHQSDHTYEIMTSDFPV 1 - 70 LDPSWTAQEEMALLEAVMDCGFGNWQDVANQMCTKTKEECEKHYMKHFINNPLFASTLLNLKQAEEAKTA 71 - 140 DTAIPFHSTDDPPRPTFDSLLSRDMAGYMPARADFIEEFDNYAEWDLRDIDFVEDDSDILHALKMAVVDI 141 - 210 YHSRLKERQRRKKIIRDHGLINLRKFQLMERRYPKEVQDLYETMRRFARIVGPVEHDKFIESHALEFELR 211 - 280 REIKRLQEYRTAGITNFCSARTYDHLKKTREEERLKRTMLSEVLQYIQDSSACQQWLRRQADIDSGLSPS 281 - 350 IPMASNSGRRSAPPLNLTGLPGTEKLNEKEKELCQMVRLVPGAYLEYKSALLNECNKQGGLRLAQARALI 351 - 420 KIDVNKTRKIYDFLIREGYITKG 421 - 443 //
